TEVA-CODEINE 15 MG — DIN 00593435
CODEINE PHOSPHATE : 15 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-CODEINE?
TEVA-CODEINE 15 MG contains CODEINE PHOSPHATE : 15 MG. It is listed in the Health Canada Drug Product Database under DIN 00593435, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Nov-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-CODEINE used for?
TEVA-CODEINE is indicated for the symptomatic treatment of mild to moderate pain of various causes and the control of exhausting, nonproductive cough which does not respond to non-opioid antitussives. TEVA-CODEINE is not indicated as an as-needed (prn) analgesic.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Codeine cost around the world?
Codeine is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Hungary publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 31 | 42 | ZAR███.██ |
| Morocco | PPV (public price) | 6 | 6 | MAD███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| United States | acquisition | 3 | 5 | USD███.██ |
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
65 pack listings across 49 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Codeine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Codeine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Codeine, across 24 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PURDUE PHARMA | 4 | 4 | CODEINE CONTIN 100MG CONTROLLED RELEASE TAB, CODEINE CONTIN 150MG CONTROLLED RELEASE TAB, CODEINE CONTIN 200MG CONTROLLED RELEASE TAB, CODEINE CONTIN 50MG CONTROLLED RELEASE TAB | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 2 | RATIO-CODEINE, TEVA-CODEINE | Sourceable in Canada |
| LABORATOIRE ATLAS INC | 2 | 2 | CODEINE PHOSPHATE SYRUP, LINCTUS CODEINE BLANC | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 2 | 1 | CODEINE 15, CODEINE 30 | Sourceable in Canada |
| D.C. LABS LIMITED | 4 | 0 | CODEINE PHOSPHATE SYRUP, CODEINE PHOSPHATE TAB 15MG, CODEINE PHOSPHATE TAB 30MG, CODEINE PHOSPHATE TAB 60MG | No marketed DIN |
| ROUGIER PHARMA DIVISION OF RATIOPHARM INC | 3 | 0 | CODEINE TAB 15MG, CODEINE TAB 30MG, PAVERAL LIQ 10MG/ML | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 2 | 0 | CODEINE PHOSPHATE INJ 30MG/ML, CODEINE PHOSPHATE INJ 60MG/ML | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-CODEINE | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | CODEINE PHOSPHATE INJECTION USP | No marketed DIN |
| STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | 1 | 0 | STANLEY SYRUP W CODEINE PHOSPHATE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 15 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Codeine |
|---|---|
| ATC code | R05DA04 |
| AHFS class | 28:08.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00593435 |
|---|---|
| DIN (unpadded, as printed on some documents) | 593435 |
| Brand name | TEVA-CODEINE |
| Generic / active ingredient | CODEINE PHOSPHATE : 15 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | NARCOTICS (CDSA I) |
| ATC code | R05DA04 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R05DA |
| Current status | MARKETED |
| Status date | 17-Nov-2017 |
| Original market date | 1983-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Codeine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PURDUE PHARMA, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 24 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CODEINE 30 | 30 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02009757 |
| CODEINE CONTIN 100MG CONTROLLED RELEASE TAB | 100 MG | TABLET (EXTENDED-RELEASE) | PURDUE PHARMA | MARKETED | 02163748 |
| CODEINE CONTIN 150MG CONTROLLED RELEASE TAB | 150 MG | TABLET (EXTENDED-RELEASE) | PURDUE PHARMA | MARKETED | 02163780 |
| CODEINE CONTIN 200MG CONTROLLED RELEASE TAB | 200 MG | TABLET (EXTENDED-RELEASE) | PURDUE PHARMA | MARKETED | 02163799 |
| CODEINE CONTIN 50MG CONTROLLED RELEASE TAB | 50 MG | TABLET (EXTENDED-RELEASE) | PURDUE PHARMA | MARKETED | 02230302 |
| CODEINE PHOSPHATE SYRUP | 25 MG / 5 ML | SYRUP | LABORATOIRE ATLAS INC | MARKETED | 00050024 |
| LINCTUS CODEINE BLANC | 10 MG / 5 ML | SOLUTION | LABORATOIRE ATLAS INC | MARKETED | 00380571 |
| TEVA-CODEINE | 30 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 00593451 |
| CODEINE 15 | 15 MG | TABLET | LABORATOIRE RIVA INC. | DORMANT | 02009889 |
| CODEINE PHOSPHATE INJ 30MG/ML | 30 MG / 1 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00497282 |
2 · Same class — other molecules in ATC R05DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Combinations | ACTIFED DM SYRUP · ACTIFED DM TABLETS · ANTITUSSIVE DECONG ANTIHISTAMINE SYR · BALMINIL DM + DECONGESTANT · +146 more | 165 | 11 | Yes |
| Dextromethorphan | ADULT HONEY WORKS · BALMINIL DM · BALMINIL DM (3MG/ML SUCROSE FREE) · BALMINIL DM CHILDREN · +75 more | 84 | 10 | Yes |
| Codeine | CODEINE 15 · CODEINE 30 · CODEINE CONTIN 100MG CONTROLLED RELEASE TAB · CODEINE CONTIN 150MG CONTROLLED RELEASE TAB · +17 more | 24 | 9 | Yes |
| Hydrocodone | HYCODAN SYRUP · HYCODAN TABLETS · PDP-HYDROCODONE · ROBIDONE 1MG/ML SYR · +1 more | 5 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R05D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R05DB | Clofedanol | 1 | 1 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| CODEINE CONTIN 100MG CONTROLLED RELEASE TAB | CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) : 100 MG | PURDUE PHARMA | MARKETED | 02163748 |
| CODEINE CONTIN 150MG CONTROLLED RELEASE TAB | CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) : 150 MG | PURDUE PHARMA | MARKETED | 02163780 |
| CODEINE CONTIN 200MG CONTROLLED RELEASE TAB | CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) : 200 MG | PURDUE PHARMA | MARKETED | 02163799 |
| CODEINE CONTIN 50MG CONTROLLED RELEASE TAB | CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) : 50 MG | PURDUE PHARMA | MARKETED | 02230302 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TEVA-CODEINE called?
The same molecule, Codeine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Brunacod | Latin | South Africa |
| Ibupain Forte | Latin | South Africa |
| Spectrapain | Latin | South Africa |
| Codef Cough | Latin | South Africa |
| Docsed | Latin | South Africa |
| Lenazine Forte | Latin | South Africa |
| Mybucod | Latin | South Africa |
| Suncodin Tablets | Latin | South Africa |
| ACTIFED COMPOUND LINCTUS | Latin | Saudi Arabia |
| Adco-Kiddipayne | Latin | South Africa |
| Adco-Metaxol | Latin | South Africa |
| AstraPain Syrup | Latin | South Africa |
| Ban Pain A/F | Latin | South Africa |
| Codeine | Latin | South Africa |
| CODETUX AD | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.